PÍLDORAS de BIOTECH
by Ysios Capital & Pharma New Talent
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 4 chart positions in 4 markets.
By chart position
- 🇩🇪DE · Life Sciences#1075K to 30K
- 🇪🇸ES · Life Sciences#6100K to 300K
- 🇦🇷AR · Life Sciences#3210K to 30K
- 🇨🇱CL · Life Sciences#683K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
59K to 185K🎙 Weekly cadence·20 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
118K to 370K🇪🇸81%🇩🇪8%🇦🇷8%+1 more - Active Followers
Loyal subscribers who consistently listen
35K to 111K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Not detected.
Recent guests
Recent episodes
El Regalo de Regeneron: Terapia Génica Gratis
Jul 2, 2026
22m 36s
Llegan las Píldoras Anti-Obesidad (La gran de Batalla Novo VS Lilly)
Jun 1, 2026
24m 26s
El récord de Tubulis (5.000 M $)
Apr 30, 2026
22m 44s
BioNTech: ARN, Amor y Exits
Apr 10, 2026
29m 04s
¿Qué está pasando en la FDA?
Mar 3, 2026
23m 21s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/2/26 | terapia génicaaudición+4 | — | RegeneronDecibel Therapeutics | — | terapia génicaRegeneron+5 | Ysios Capital | 22m 36s | ||
| 6/1/26 | obesitypharmaceutical industry+4 | — | Wegovy OralOrforglipron+7 | — | obesityWegovy Oral+7 | — | 24m 26s | ||
| 4/30/26 | cancer treatmentbiotech innovation+4 | — | Revolution MedicinesGilead Sciences+3 | USAAlemania | cancerpancreatic cancer+6 | — | 22m 44s | ||
| 4/10/26 | BioNTechARN mensajero+4 | — | BioNTechGanymed+2 | AlemaniaTurquía+1 | BioNTechARN mensajero+5 | — | 29m 04s | ||
| 3/3/26 | FDAModerna vaccine+4 | — | FDAModerna+1 | — | FDAModerna+6 | Ysios Capital | 23m 21s | ||
| 2/2/26 | Mergers and AcquisitionsBiotech Industry+4 | Joan Perelló | MerckCidara+6 | — | M&ABiotech+8 | — | 37m 14s | ||
| 12/11/25 | BiotechPharma+4 | — | Pharma New TalentNovo+4 | Estados Unidos | BiotechPharma+7 | Ysios Capital | 32m 21s | ||
| 11/18/25 | FDA approvalmitochondrial disease+3 | Dr.Ramon Martí | nuevo tratamientoVall d’Hebron Research Institute+2 | BarcelonaCalifornia+1 | FDAmitochondrial disease+5 | — | 28m 11s | ||
| 10/30/25 | biotech acquisitiononcology+4 | — | PetosentamabGenmab+2 | BarcelonaEspaña | biotechGenmab+7 | Ysios Capital | 22m 55s | ||
| 9/26/25 | biotechclinical trials+4 | — | ObefazimodAbivax | FranciaBig Biotech europeo | AbivaxObefazimod+6 | — | 27m 33s | ||
| 7/17/25 | biotech ecosystemEuropean biotech+3 | — | Ysios CapitalSpliceBio+10 | — | biotechEurope+7 | — | 26m 38s | ||
| 6/11/25 | biotech fundingentrepreneurship+3 | Miquel Vila i PerellóJordi Xiol | InteínasSplice Bio+2 | EspañaChina | biotechfunding+5 | Ysios Capital | 35m 31s |
Showing 12 of 12
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for PÍLDORAS de BIOTECH
Peaked at #6 in Spain, top 10 in 1 of 5 tracked markets, currently #6 in Spain.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Spain | — | #6 | #6 | — |
| AR | — | #32 | #32 | — |
| CL | — | #68 | #68 | — |
| Spain | — | #102 | #102 | — |
| Germany | — | #107 | #107 | — |
Chart Positions
5 placements across 4 markets.
Chart Positions
5 placements across 4 markets.